Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Palvella Therapeutics ( (PVLA) ) has shared an announcement.
Palvella Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting the progress in its rare disease pipeline. The company is advancing its QTORIN rapamycin product candidates, with significant upcoming milestones including the Phase 2 TOIVA trial results for cutaneous venous malformations expected in mid-December 2025 and Phase 3 SELVA trial results for microcystic lymphatic malformations anticipated in the first quarter of 2026. Additionally, Palvella announced the development of QTORIN pitavastatin for disseminated superficial actinic porokeratosis, with a Phase 2 study planned for the second half of 2026. The company also reported cash reserves of $63.6 million as of September 30, 2025, expected to fund operations into the second half of 2027.
The most recent analyst rating on (PVLA) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases that currently have no FDA-approved treatments. The company is advancing its QTORIN-derived product candidates across multiple rare skin conditions, aiming to be the first to provide FDA-approved therapies for these underserved communities.
Average Trading Volume: 168,163
Technical Sentiment Signal: Hold
Current Market Cap: $860.8M
Find detailed analytics on PVLA stock on TipRanks’ Stock Analysis page.